Wantai Canghai

Beijing Wantai Canghai Biotechnology is a prominent Chinese biopharmaceutical firm focused on the development and large-scale production of recombinant vaccines. As a key subsidiary of Beijing Wantai Biological Pharmacy Enterprise, the company achieved global recognition for launching Hecolin, the world's first Hepatitis E vaccine, and Cecolin, China's first domestic HPV vaccine. Their proprietary technology platform utilizes E. coli for the expression of virus-like particles (VLPs), offering a cost-effective alternative to traditional eukaryotic expression systems. The company continues to advance a deep pipeline, including a 9-valent HPV vaccine and next-generation infectious disease preventatives, often in collaboration with Xiamen University. Wantai Canghai plays a critical role in global health by providing affordable vaccine options for low- and middle-income countries through partnerships with organizations like PATH and the WHO.